Core Peptides vs SwissChems — US head-to-head 2026

Core Peptides (US-domestic, Editor's Choice 9.2) and SwissChems (US-shipping, 8.4) are the two most-discussed US peptide vendors. They differ on catalog scope (peptide-only vs SARMs+peptides), affiliate commission (10% vs 20%), domestic vs international warehousing, and regulatory profile. This head-to-head compares them across the methodology axes.

Catalog scope: Core Peptides is peptide-only (BPC-157, TB-500, GHK-Cu, Selank, Semax, Epithalon, growth-hormone secretagogues, melanotans, etc). SwissChems is dual-catalogue — SARMs (Ostarine, RAD-140, LGD-4033, etc) plus peptides. The dual-catalogue brings broader product range but attracts more regulatory attention because SARMs are state-scheduled in California and several other states.

Testing: Core Peptides ships HPLC + LC-MS + endotoxin verified COAs at 99.1% stated purity. SwissChems ships HPLC + LC-MS verified at 99.3% stated purity. Both are methodology-acceptable testing depths; Core Peptides adds endotoxin testing, SwissChems has slightly higher stated purity. Neither has documented third-party blind multi-lab testing equivalent to Particle Peptides EU.

Affiliate commission: SwissChems 20%, Core Peptides 10%. SwissChems has the highest affiliate commission in the US segment, making it the favoured choice for content creators. PeptideGuide discloses every affiliate relationship at /disclosures and the methodology weighting puts trust + testing ahead of commission.

Regulatory profile: Core Peptides operates peptide-only with strict research-use-only labelling. The peptide-only catalog has cleaner regulatory profile. SwissChems' dual SARMs+peptides catalog brings more enforcement attention. Recent US peptide segment shutdowns (Amino Asylum FDA raid June 2025, Peptide Sciences voluntary March 2026) reinforce that vendors with dual-catalogue or therapeutic-claim positioning face higher risk.

Verdict: Core Peptides wins for US-domestic researchers prioritising regulatory cleanliness, fast shipping, and peptide-focused operation. SwissChems wins for content creators (highest commission) and researchers needing broader catalog including SARMs. Both are operationally sound; the choice depends on use case.

Plain-language summary

Core Peptides is Editor's Choice for US-domestic peptide-only research with clean regulatory profile. SwissChems is the choice for content creators (20% commission) and broader SARMs+peptides catalog. The decision turns on whether you need SARMs and whether commission rate matters.

Verdict

✓Pros

Core Peptides: peptide-only catalog — cleaner regulatory profile
Core Peptides: US-domestic 2-4 day shipping, no customs
SwissChems: 20% affiliate commission — highest in US segment
SwissChems: broader catalog including SARMs

×Cons

SwissChems: dual SARMs+peptides catalog attracts more regulatory attention
SwissChems: SARMs state-scheduled in CA + others — verify locally
Core Peptides: smaller catalog than SwissChems
Both: HPLC + LC-MS only — no third-party blind multi-lab testing

Legal status

Both operate under FDA / FTC / DEA framework. Core Peptides peptide-only; SwissChems dual SARMs+peptides. State-level Prop 65 + SARM scheduling considerations apply. Both maintain research-use-only labelling.

FAQ

Should content creators use SwissChems for the affiliate?

SwissChems' 20% commission is the highest in the US segment. For affiliate-driven content, that's a meaningful revenue advantage. Disclosure is required under FTC Endorsement Guides (16 CFR Part 255) — see /disclosures.

Is the SARMs catalog risky for me?

Buying peptides from a SARM-selling vendor doesn't turn the peptide into a SARM. SARMs are state-scheduled in California and several other states; peptides are not. The dual-catalogue puts more regulatory attention on the vendor (and could disrupt supply continuity if enforcement hits) but doesn't change the legal status of the peptide you ordered.

Why is Core Peptides Editor's Choice over SwissChems?

Methodology weights trust history + EU/regional friendliness + testing depth. Core Peptides' US-domestic operation, peptide-only catalog, and clean regulatory profile score higher than SwissChems' commission advantage. The methodology favours regulatory cleanliness over commission rate.

Can I order from both?

Yes. Many US researchers use Core Peptides as primary and SwissChems for SARMs or for specific products Core Peptides doesn't carry. The two are complementary rather than competing.

What about Amino Asylum and Peptide Sciences?

Both are no longer operating. Amino Asylum FDA-raided June 2025 (therapeutic-claim marketing); Peptide Sciences voluntary shutdown 2026-03-06. Do not order from legacy domains.